197 related articles for article (PubMed ID: 21792892)
1. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.
Hatiboglu MA; Kong LY; Wei J; Wang Y; McEnery KA; Fuller GN; Qiao W; Davies MA; Priebe W; Heimberger AB
Int J Cancer; 2012 Jul; 131(1):8-17. PubMed ID: 21792892
[TBL] [Abstract][Full Text] [Related]
2. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells.
Kong LY; Abou-Ghazal MK; Wei J; Chakraborty A; Sun W; Qiao W; Fuller GN; Fokt I; Grimm EA; Schmittling RJ; Archer GE; Sampson JH; Priebe W; Heimberger AB
Clin Cancer Res; 2008 Sep; 14(18):5759-68. PubMed ID: 18794085
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model.
Kong LY; Gelbard A; Wei J; Reina-Ortiz C; Wang Y; Yang EC; Hailemichael Y; Fokt I; Jayakumar A; Qiao W; Fuller GN; Overwijk WW; Priebe W; Heimberger AB
Clin Cancer Res; 2010 May; 16(9):2550-61. PubMed ID: 20388845
[TBL] [Abstract][Full Text] [Related]
4. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.
Kong LY; Wei J; Sharma AK; Barr J; Abou-Ghazal MK; Fokt I; Weinberg J; Rao G; Grimm E; Priebe W; Heimberger AB
Cancer Immunol Immunother; 2009 Jul; 58(7):1023-32. PubMed ID: 19002459
[TBL] [Abstract][Full Text] [Related]
5. Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy.
Assi HH; Paran C; VanderVeen N; Savakus J; Doherty R; Petruzzella E; Hoeschele JD; Appelman H; Raptis L; Mikkelsen T; Lowenstein PR; Castro MG
J Pharmacol Exp Ther; 2014 Jun; 349(3):458-69. PubMed ID: 24696041
[TBL] [Abstract][Full Text] [Related]
6. Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy.
Ott M; Kassab C; Marisetty A; Hashimoto Y; Wei J; Zamler D; Leu JS; Tomaszowski KH; Sabbagh A; Fang D; Gupta P; Priebe W; Zielinski RJ; Burks JK; Long JP; Kong LY; Fuller GN; DeGroot J; Sulman EP; Heimberger AB
Clin Cancer Res; 2020 Sep; 26(18):4983-4994. PubMed ID: 32605912
[TBL] [Abstract][Full Text] [Related]
7. STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo.
Zhou X; Ren Y; Liu A; Han L; Zhang K; Li S; Li P; Li P; Kang C; Wang X; Zhang L
Oncol Rep; 2014 May; 31(5):2173-80. PubMed ID: 24676554
[TBL] [Abstract][Full Text] [Related]
8. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P
Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391
[TBL] [Abstract][Full Text] [Related]
9. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.
Horiguchi A; Asano T; Kuroda K; Sato A; Asakuma J; Ito K; Hayakawa M; Sumitomo M; Asano T
Br J Cancer; 2010 May; 102(11):1592-9. PubMed ID: 20461084
[TBL] [Abstract][Full Text] [Related]
10. Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells.
Lee HT; Xue J; Chou PC; Zhou A; Yang P; Conrad CA; Aldape KD; Priebe W; Patterson C; Sawaya R; Xie K; Huang S
Oncotarget; 2015 Apr; 6(12):10016-29. PubMed ID: 25881542
[TBL] [Abstract][Full Text] [Related]
11. Convection-enhanced delivery of sorafenib and suppression of tumor progression in a murine model of brain melanoma through the inhibition of signal transducer and activator of transcription 3.
Zou Z; Yin Y; Lin J; Hsu LC; Brandon VL; Yang F; Jove R; Jandial R; Li G; Chen MY
J Neurosurg; 2016 May; 124(5):1310-8. PubMed ID: 26544779
[TBL] [Abstract][Full Text] [Related]
12. The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells.
Lu K; Chen N; Zhou XX; Ge XL; Feng LL; Li PP; Li XY; Geng LY; Wang X
Biochem Biophys Res Commun; 2015 Aug; 464(1):292-8. PubMed ID: 26116769
[TBL] [Abstract][Full Text] [Related]
13. STAT3 inhibitor WP1066 as a novel therapeutic agent for bCCI neuropathic pain rats.
Xue ZJ; Shen L; Wang ZY; Hui SY; Huang YG; Ma C
Brain Res; 2014 Oct; 1583():79-88. PubMed ID: 25084036
[TBL] [Abstract][Full Text] [Related]
14. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
[TBL] [Abstract][Full Text] [Related]
15. WP1066 suppresses macrophage cell death induced by inflammasome agonists independently of its inhibitory effect on STAT3.
Honda S; Sadatomi D; Yamamura Y; Nakashioya K; Tanimura S; Takeda K
Cancer Sci; 2017 Mar; 108(3):520-527. PubMed ID: 28035720
[TBL] [Abstract][Full Text] [Related]
16. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo.
Iwamaru A; Szymanski S; Iwado E; Aoki H; Yokoyama T; Fokt I; Hess K; Conrad C; Madden T; Sawaya R; Kondo S; Priebe W; Kondo Y
Oncogene; 2007 Apr; 26(17):2435-44. PubMed ID: 17043651
[TBL] [Abstract][Full Text] [Related]
17. Delayed Administration of WP1066, an STAT3 Inhibitor, Ameliorates Radiation-Induced Lung Injury in Mice.
Yu J; Yuan X; Liu Y; Zhang K; Wang J; Zhang H; Liu F
Lung; 2016 Feb; 194(1):67-74. PubMed ID: 26563331
[TBL] [Abstract][Full Text] [Related]
18. [Signal transducer and activator of transcription-3 inhibitor WP1066 affects human tongue squamous cell carcinoma proliferation and apoptosis in vitro and in vivo].
Huang Y; Zhou X; Liu A; Li S; Wang X; Zhang L
Zhonghua Kou Qiang Yi Xue Za Zhi; 2014 May; 49(5):308-13. PubMed ID: 25031007
[TBL] [Abstract][Full Text] [Related]
19. The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
Lu K; Fang XS; Feng LL; Jiang YJ; Zhou XX; Liu X; Li PP; Chen N; Ding M; Wang N; Zhang J; Wang X
Cancer Lett; 2015 Apr; 359(2):250-8. PubMed ID: 25636517
[TBL] [Abstract][Full Text] [Related]
20. Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug.
Sau S; Mondal SK; Kashaw SK; Iyer AK; Banerjee R
Mol Cell Biochem; 2017 Dec; 436(1-2):119-136. PubMed ID: 28585089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
